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Background
Magnesium sulfate is neuroprotective in preclinical models of stroke and has 
shown signals of potential efficacy with an acceptable safety profile when delivered 
early after stroke onset in humans. Delayed initiation of neuroprotective agents has 
hindered earlier phase 3 trials of neuroprotective agents.
Methods
We randomly assigned patients with suspected stroke to receive either intravenous 
magnesium sulfate or placebo, beginning within 2 hours after symptom onset. A load-
ing dose was initiated by paramedics before the patient arrived at the hospital, and a 
24-hour maintenance infusion was started on the patient’s arrival at the hospital. The 
primary outcome was the degree of disability at 90 days, as measured by scores on the 
modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability).
Results
Among the 1700 enrolled patients (857 in the magnesium group and 843 in the pla-
cebo group), the mean (±SD) age was 69±13 years, 42.6% were women, and the mean 
pretreatment score on the Los Angeles Motor Scale of stroke severity (range, 0 to 10, 
with higher scores indicating greater motor deficits) was 3.7±1.3. The final diagnosis 
of the qualifying event was cerebral ischemia in 73.3% of patients, intracranial hem-
orrhage in 22.8%, and a stroke-mimicking condition in 3.9%. The median interval 
between the time the patient was last known to be free of stroke symptoms and the 
start of the study-drug infusion was 45 minutes (interquartile range, 35 to 62), and 
74.3% of patients received the study-drug infusion within the first hour after symp-
tom onset. There was no significant shift in the distribution of 90-day disability 
outcomes on the global modified Rankin scale between patients in the magnesium 
group and those in the placebo group (P = 0.28 by the Cochran–Mantel–Haenszel 
test); mean scores at 90 days did not differ between the magnesium group and the 
placebo group (2.7 in each group, P = 1.00). No significant between-group differences 
were noted with respect to mortality (15.4% in the magnesium group and 15.5% in 
the placebo group, P = 0.95) or all serious adverse events.
Conclusions
Prehospital initiation of magnesium sulfate therapy was safe and allowed the start 
of therapy within 2 hours after the onset of stroke symptoms, but it did not improve 
disability outcomes at 90 days. (Funded by the National Institute of Neurological 
Disorders and Stroke; FAST-MAG ClinicalTrials.gov number, NCT00059332.)
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Stroke is the second leading cause of death and a leading cause of adult disability worldwide. Unfortunately, currently avail-
able therapies for acute ischemic stroke, which 
are all reperfusion-based, are only moderately ef-
fective.1,2 Treatment with tissue plasminogen ac-
tivator (t-PA), the only pharmacologic treatment 
approved by a regulatory agency for the treatment 
of acute ischemic stroke, results in early reperfu-
sion in less than half of treated patients, can be 
started only after neuroimaging has ruled out 
intracerebral hemorrhage, and is used in only 2 to 
7% of patients with acute ischemic stroke in the 
United States.1 Mechanical thrombectomy devices 
improve patient outcomes but must be deployed 
even later than thrombolytic agents, after substan-
tial injury has accumulated, and they yield inde-
pendent functional outcomes in only 33 to 37% 
of treated patients.3,4
Neuroprotection is a promising treatment 
strategy that is complementary to reperfusion. 
Neuroprotective agents interrupt the cellular, bio-
chemical, and metabolic processes that mediate 
cerebral-tissue injury during or after ischemia. 
Because they are typically safe and potentially ben-
eficial in patients with hemorrhagic stroke as well 
as in those with ischemic stroke, neuroprotective 
agents can, in principle, be given before brain 
imaging is performed, including in the prehos-
pital setting, to stabilize threatened tissues until 
therapeutic or spontaneous reperfusion. More than 
70 neuroprotective agents have been tested in ran-
domized, controlled clinical trials involving pa-
tients with acute ischemic stroke, and no agent 
has been shown in definitive phase 3 trials to be 
unequivocally beneficial.5 However, the crucial fac-
tor of delayed time to treatment hindered all the 
trials. Although neuroprotective agents were most 
beneficial in rodent and primate models of focal 
stroke when administered in the first 2 hours after 
onset, no prior clinical trial of a neuroprotective 
agent has enrolled any substantial cohort of pa-
tients during this time window.5,6
Initiating potentially neuroprotective therapies 
very soon after symptom onset appears to be criti-
cal if the dramatic benefits of neuroprotective 
agents that are evident in the laboratory are to be 
achieved in patients with stroke. Enrolling patients 
in the field is a promising approach to the chal-
lenge of testing neuroprotective agents in the 
hyperacute phase of stroke. Magnesium sulfate is 
reliably cerebroprotective in diverse animal mod-
els of stroke, exerting both vasodilatory and di-
rect neuroprotective and glioprotective effects.7-9 
Moreover, magnesium is inexpensive, widely avail-
able, and simple to administer and also has a fa-
vorable adverse-event profile as a standard treat-
ment for eclampsia and preeclampsia.8,10 A pivotal 
trial of magnesium sulfate in patients with stroke 
showed no benefit when the agent was adminis-
tered a median of 7.4 hours after onset but sug-
gested potential efficacy in the subgroup of pa-
tients treated within the first 3 hours after 
onset.11 After a pilot trial showed that prehospi-
tal initiation of magnesium sulfate was feasible 
and generally safe and that it accelerated the start 
of the study agent by 2 hours as compared with 
in-hospital initiation,12 we undertook a pivotal 
trial of initiation of magnesium sulfate therapy 
within 2 hours after the onset of symptoms.
Me thods
Study Design and Oversight
The Field Administration of Stroke Therapy–
Magnesium (FAST-MAG) phase 3 trial was a mul-
ticenter, randomized, double-blind, placebo-con-
trolled, pivotal clinical trial. A total of 315 
paramedic-staffed ambulances and 60 receiving 
hospital sites in Los Angeles and Orange Coun-
ties, California, participated in the study. Details 
of the study rationale and methods have been 
published previously.13,14 Our hypothesis was that 
initiation of the neuroprotective agent magne-
sium sulfate by paramedics in the field would im-
prove the long-term functional outcome of patients 
with acute stroke. A broader systems goal was to 
show that enrollment and treatment of patients 
with acute stroke in the field is a practical and 
feasible strategy for phase 3 trials.
The members of the executive committee and 
investigators at the study sites (Table S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org) designed the trial, 
collected the data, and performed the data analy-
sis. These investigators vouch for the accuracy and 
completeness of the data and analysis and for the 
fidelity of this report to the study protocol and 
statistical analysis plan, available at NEJM.org. 
The trial was funded by the National Institute of 
Neurological Disorders and Stroke, which ap-
pointed a data and safety monitoring board that 
oversaw the conduct of the trial. Safety events were 
adjudicated by an independent medical monitor. 
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The study protocol was approved by the institu-
tional review board at each prehospital and hos-
pital study site.
Patient Selection
Patients 40 to 95 years of age were eligible for in-
clusion if they had a suspected stroke as deter-
mined with the use of the modified Los Angeles 
Prehospital Stroke Screen (LAPSS)13,15 and if treat-
ment initiation could occur within 2 hours after 
the patient was last known to be free of stroke 
symptoms. Details of the study inclusion and ex-
clusion criteria are provided in Table S2 in the Sup-
plementary Appendix. The use of the modified 
LAPSS to assess suspected stroke ensured that all 
patients had motor deficits on entry. Pretreatment 
severity of stroke was assessed with the use of the 
Los Angeles Motor Scale (LAMS), on which scores 
range from 0 to 10, with higher scores indicating 
more severe motor weakness. For patients being 
transported to all hospital sites, written informed 
consent was obtained from the patients, if they 
were deemed competent to provide it, or from their 
legally authorized representatives, if they were 
available on scene. In addition, for transports to 
36 hospital sites, when patients were not deemed 
competent and had no legally authorized repre-
sentative present but were with an adult who knew 
them well, enrollment was allowed under rules for 
exemption from informed-consent requirements 
in emergency research regulations.
Randomization and Treatment
Patients were randomly assigned, in 1:1 ratio, to 
receive a magnesium sulfate or a placebo infusion. 
Randomization was stratified according to en-
rolling ambulance. Each ambulance was stocked 
with one study kit at a time, containing the next 
assignment in its permuted-block sequence.
Magnesium sulfate or matching placebo was 
administered intravenously as a 15-minute bolus 
infusion followed by a 24-hour maintenance in-
fusion. In the active-treatment group, the bolus 
dose contained 4 g of magnesium sulfate in 54 ml 
of normal saline infused over a period of 15 min-
utes; the maintenance infusion contained 16 g of 
magnesium sulfate diluted in 240 ml of 0.9% 
normal saline, infused at a rate of 10 ml per hour 
for 24 hours. Paramedics in the field initiated the 
bolus dose through infusion tubing with a fixed 
lumen size that automatically implemented rate 
control of gravity-driven infusion. Nurses started 
the maintenance infusion in the emergency de-
partment immediately after completion of the 
loading dose, using electronic infusion pumps.
Concomitant therapy followed national practice 
guidelines from the American Heart Association 
and American Stroke Association.16,17 Patients 
with ischemic stroke could be treated with intra-
venous t-PA up to 4.5 hours after the last known 
time before the onset of stroke symptoms and 
with neurothrombectomy devices approved by the 
Food and Drug Administration.
Outcomes
The primary outcome was the degree of disability, 
as assessed with the use of the modified Rankin 
scale, 3 months after a stroke. Scores on the scale 
range from 0 to 6, with higher scores indicating 
greater disability. To ensure reliable scoring, raters 
used the Rankin Focused Assessment.18 For the 
primary analysis, shifts in outcome across all sev-
en levels of the modified Rankin scale were ana-
lyzed. Additional outcome measures that were as-
sessed at day 90 included the level of activities of 
daily living, according to the Barthel Index (range, 
0 to 100, with higher values indicating more in-
dependence); the degree of neurologic deficit, ac-
cording to scores on the National Institutes of 
Health Stroke Scale (NIHSS; range, 0 to 42, with 
higher scores indicating more severe deficits); and 
overall functional outcome, according to scores on 
the Glasgow Outcome Scale (GOS; range, 1 to 5, 
with higher scores indicating worse function). 
Hierarchically prespecified secondary end points 
at day 90 included excellent recovery (modified 
Rankin score of 0 or 1, Barthel Index ≥95, NIHSS 
score of 0 or 1, and GOS score of 1, with the 
outcomes analyzed simultaneously with the use of 
the global test statistic),19 minimal or no disability 
(modified Rankin score of 0 or 1), neurologic def-
icit (as assessed by the NIHSS score), good recov-
ery (modified Rankin score ≤2, Barthel Index ≥60, 
NIHSS score ≤8, and GOS score of 1 or 2, with the 
outcomes analyzed simultaneously with the use 
of the global test statistic), functional indepen-
dence (modified Rankin score ≤2), and death.
Statistical Analysis
In calculating the sample size, we projected that 
treatment would be beneficial in patients with 
cerebral ischemia and have a neutral effect in pa-
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tients with intracranial hemorrhage or a stroke-
mimicking condition. We made one interim adjust-
ment to the sample size to account for a higher 
proportion of enrolled patients with intracere-
bral hemorrhage than projected, increasing the 
planned sample from 1298 to 1700 patients.13 
Among patients with cerebral ischemia, the shift 
in outcome distribution of the modified Rankin 
scale was projected to be approximately 70% of 
the effect observed in a meta-analysis of phase 2 
trials of magnesium.9 The primary efficacy eval-
uation tested the null hypothesis that the distri-
bution of modified Rankin scores at day 90 would 
be identical in the magnesium and placebo groups, 
versus the one-sided alternative that the distribu-
tion of scores would shift lower in the magnesium 
group, with a probability of type I error of 0.05 
and a probability of type II error of 0.20. Three 
interim efficacy analyses were performed with the 
use of an O’Brien and Fleming–type alpha-spend-
ing function. The primary hypothesis was assessed 
with the use of the Cochran–Mantel–Haenszel test, 
with adjustment for baseline severity of stroke 
(LAMS score of 0 to 3 vs. 4 or 5), age (<70 years 
vs. ≥70 years), the presence or absence of prestroke 
disability, and the geographic region of the en-
rolling ambulance. The P values for the primary 
hypothesis are one-sided; all other P values are 
two-sided.
R esult s
Study Patients
Between January 2005 and December 2012, a total 
of 1700 patients underwent randomization: 857 
were assigned to the magnesium-sulfate group and 
843 to the placebo group. Figure S1 in the Supple-
mentary Appendix shows the screening, random-
ization, treatment, and follow-up of the patients.
Demographic and clinical characteristics 
were similar in the two study groups (Table 1). 
The mean (±SD) age was 69±13 years, and 42.6% 
of the patients were women. Final diagnoses of 
the qualifying event were cerebral ischemia in 
73.3% of the patients, intracranial hemorrhage 
in 22.8%, and a stroke-mimicking condition in 
3.9%. The mean pretreatment LAMS score was 
3.7±1.3. The mode of consent was explicit writ-
ten informed consent from the patient in the 
case of 1017 patients (59.8%), explicit written 
informed consent from a legally authorized rep-
resentative in the case of 662 (38.9%), and initial 
exemption from explicit informed consent in the 
case of 21 (1.2%).
With regard to the systems goal of delivering 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Placebo
(N = 843)
Magnesium
(N = 857)
Age — yr 69±14 69±13
Female sex — no. (%) 367 (43.5) 358 (41.8)
Race — no. (%)†
White 661 (78.4) 664 (77.5)
Black 113 (13.4) 106 (12.4)
Asian 62 (7.4) 77 (9.0)
Other 7 (0.8) 10 (1.2)
Hispanic ethnic group — no. (%)† 206 (24.4) 196 (22.9)
Medical history — no. (%)
Hypertension 648 (76.9) 671 (78.3)
Diabetes 188 (22.3) 189 (22.1)
Hyperlipidemia 407 (48.3) 398 (46.4)
Atrial fibrillation 175 (20.8) 194 (22.6)
Myocardial infarction 82 (9.7)  94 (11.0)
Tobacco use‡ 158 (18.7) 139 (16.2)
Alcohol use§ 328 (38.9) 326 (38.0)
Prestroke function
Living at home — no. (%) 823 (97.6) 834 (97.3)
Prestroke modified Rankin score — 
median (interquartile range)¶
0 (0 – 0)  0 (0 – 0)
Early severity of neurologic deficit
LAMS score before treatment‖ 3.7±1.3 3.7±1.3
NIHSS score in hospital** 11.2±9.8 11.5±9.0
Glucose level on arrival at hospital — 
mg/dl
136.5±52.0 133.7±50.5
Final diagnosis — no./total no. (%)
Cerebral ischemia 613/842 (72.8) 632/857 (73.7)
Intracranial hemorrhage 192/842 (22.8) 195/857 (22.8)
Stroke-mimicking condition 37/842 (4.4) 30/857 (3.5)
Intravenous t-PA in patients with cere-
bral ischemia — no./total no. (%)
205/613 (33.4) 242/632 (38.3)
* Plus–minus values are means ±SD. There were no significant differences between 
the two study groups. The term t-PA denotes tissue plasminogen activator.
† Race and ethnic group were self-reported.
‡ Values reflect current use or use within the previous 12 months.
§ Values reflect current use.
¶ Scores on the modified Rankin scale range from 0 to 6, with higher scores 
indicating more severe disability.
‖ Scores on the Los Angeles Motor Scale (LAMS) range from 0 to 10, with 
higher scores indicating more severe motor weakness.
** Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 
0 to 42, with higher scores indicating more severe neurologic deficits.
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the study intervention to patients rapidly, the me-
dian time from the last known time before the 
onset of stroke symptoms to the start of study-
drug infusion was 45 minutes (interquartile 
range, 35 to 62) (Table 2). Overall, 74.3% of the 
patients received the study drug in the first 60 
minutes after symptom onset and 24.7% in the 
following 60 minutes.
Primary Outcome
There was no significant shift in the distribution 
of 90-day disability outcomes on the global mod-
ified Rankin scale between patients in the mag-
nesium group and those in the placebo group 
(P = 0.28 by the Cochran–Mantel–Haenszel test) 
(Fig. 1). Similarly, mean scores on the modified 
Rankin scale at 90 days did not differ between the 
magnesium group and the placebo group (2.7 in 
each group, P = 1.00).
Secondary Outcomes
No benefit of magnesium sulfate therapy was seen 
with respect to the five prespecified secondary 90-
day efficacy end points of excellent recovery, min-
imal or no disability, neurologic deficit, good re-
covery, and functional independence (Table 3). 
Analyses did not show heterogeneity of treatment 
effect according to baseline covariate in the pre-
specified subgroups defined according to type of 
stroke (cerebral ischemia vs. intracranial hemor-
rhage), concomitant therapy with t-PA (yes vs. no), 
time from onset of stroke symptoms to treatment 
(≤60 minutes vs. 61 to 120 minutes), age (<70 years 
vs. ≥70 years), sex, race, and pretreatment severity 
of stroke (LAMS score of 0 to 3 vs. 4 or 5). Homo-
geneity of effect was seen in the distribution of 
modified Rankin scores across all seven levels 
and was also seen when modified Rankin scores 
were dichotomized as 0 or 1 versus 2 to 6 (Fig. S3 
in the Supplementary Appendix) and 0 to 2 ver-
sus 3 to 6.
Safety
In the overall cohort, the 90-day rate of death was 
15.5%, the rate of symptomatic hemorrhagic trans-
formation of initial cerebral ischemia was 2.7%, 
and rate of asymptomatic hemorrhagic transfor-
mation was 6.3%. These rates did not differ sig-
nificantly between the two study groups.
The rate of serious adverse events did not dif-
fer significantly between the magnesium group 
and the placebo group, overall (51.2% vs. 50.1%, 
Table 2. Time Intervals.*
Interval
Placebo
(N = 843)
Magnesium
(N = 857)
Total
(N = 1700)
Symptom onset to study-drug administration
Median — min 46 45 45
Interquartile range — min 36–62 35–60 35–62
Distribution — no./total no. (%)
0–60 min 612/836 (73.2) 641/851 (75.3) 1253/1687 (74.3)
61–120 min 215/836 (25.7) 202/851 (23.7) 417/1687 (24.7)
>120 min 9/836 (1.1) 8/851 (0.9) 17/1687 (1.0)
Initiation of 911 call to study-drug administration — min
Median 30 30 30
Interquartile range 26–34 25–35 25–34
Paramedic on scene to study-drug administration — min
Median 23 23 23
Interquartile range 19–28 18–27 18–27
Paramedic on scene to patient arrival at hospital — min
Median 33 32 33
Interquartile range 27–39 27–39 27–39
* There were no significant differences between the two study groups.
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P = 0.67) (Table 3) or when assessed according to 
major organ groups (Table S3 in the Supplemen-
tary Appendix). Systolic blood pressure was 
slightly lower (by ≤3 mm Hg) in the magnesium 
group than in the placebo group at the end of 
the 15-minute infusion of the loading dose and 
from hour 20 to hour 32 after the start of the 
maintenance dose (24-hour infusion) but not from 
hour 1 to hour 16 after the start of the mainte-
nance dose (Table S4 in the Supplementary Ap-
pendix).
Discussion
The FAST-MAG phase 3 trial did not confirm the 
primary hypothesis that prehospital initiation of 
magnesium sulfate in patients with a suspected 
stroke during the hyperacute phase would reduce 
the level of disability at 90 days. There was no 
significant difference in mortality, and the over-
all number of serious adverse events was similar 
in the magnesium group and the placebo group. 
The study achieved its systems aim of delivering 
the study agent to patients with stroke faster than 
in previous phase 3 trials, with nearly three quar-
ters of the patients treated in the “golden hour,” the 
first 60 minutes after the onset of stroke.20
There are several potential explanations for 
the neutral results with respect to magnesium 
sulfate. Magnesium trafficking across the blood–
brain barrier is not immediate. The concentra-
tion of magnesium in the cerebrospinal fluid 
peaks 4 hours after parenteral administration in 
the presence of an intact blood–brain barrier and 
more quickly in regions of focal ischemia where 
the blood–brain barrier is disrupted.9 Magnesium 
sulfate may not have accumulated in brain tissues 
quickly enough to yield a benefit despite rapid 
attainment of increased serum levels. In addition, 
a single neuroprotective agent may not interdict 
enough pathways in the molecular elaboration of 
ischemic injury, and combinations of agents or 
agents with highly pleiotropic effects may be 
required.21
In addition to testing magnesium sulfate spe-
cifically, we performed the FAST-MAG trial with 
the broad central aim of developing and validating 
methods that can be used in pivotal trials of neu-
roprotective treatments in the prehospital setting. 
To identify patients with a suspected stroke for 
enrollment in the study, we used a two-stage 
screening process. First, paramedics identified 
potential patients using a modified version of the 
LAPSS, a validated eight-item inventory that takes 
1 or 2 minutes to perform.15 Then the patient was 
further assessed by an enrolling physician-inves-
tigator, who reviewed the patient’s condition by 
means of a cell-phone call with the paramedic 
and the patient or on-scene legally authorized 
representative. This approach reduced the propor-
tion of enrolled patients with stroke-mimicking 
conditions to 3.9%, a proportion that is less than 
the 5% projected in sample-size calculations.
To maximize patient autonomy and respect for 
persons, whenever a competent patient or on-scene 
legally authorized representative was present, ex-
plicit written informed consent was obtained, 
elicited by a physician-investigator speaking with 
the consent provider by cell phone, with the use 
of consent forms carried in the vehicle. A simul-
taneous-ring, voice-over-Internet phone system 
connected consent providers immediately to 
English- or Spanish-speaking physician-consent 
elicitors.22 This approach ensured knowledgeable 
responses to consent providers’ queries and was 
performed in parallel with standard paramedic 
prehospital activities to avoid delays in care. The 
system succeeded in enabling informed consent 
without delay of care. Overall, 99% of the patients 
were enrolled with the use of explicit informed 
Placebo
Magnesium
Modified Rankin Scale
0 1 2 3 4 5 6
18.7 16.3 18.4 13.3 10.5 10.1 12.7
18.4 13.316.2 18.3 10.6 10.2 13.0
Figure 1. Functional Outcomes at 90 Days in the Magnesium and Placebo 
Groups, According to Score on the Modified Rankin Scale.
The primary outcome was a shift toward a more favorable distribution 
across the seven levels of the modified Rankin scale. Scores on the scale 
range from 0 to 6, with higher scores indicating increased disability. The 
figure shows the distribution after adjustment for pretreatment severity  
of stroke, age, the presence or absence of prestroke disability, and geo-
graphic region; values indicate percentage of patients. (Fig. S2 in the  
Supplementary Appendix shows the raw distribution of modified Rankin 
scores at 3 months.) There was no significant shift in the distribution of 
90-day disability outcomes on the global modified Rankin scale between 
patients in the magnesium group and those in the placebo group (P = 0.28 
by the Cochran–Mantel–Haenszel test).
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consent, and the median interval from the para-
medics’ arrival on the scene to the patient’s ar-
rival at the emergency department (33 minutes) 
was similar to that in our catchment area before 
the initiation of the trial (34 minutes) and in 
other localities during the time the study was 
ongoing (34 minutes).12,23
Additional important techniques that we used 
in this trial included having paramedics rate the 
pretreatment severity of stroke with the use of 
the LAMS, prestocking ambulances with the sin-
gle next kit in the permuted-block randomization 
sequence (blinded, pre-encounter randomization), 
using gravity-controlled tubing to enable paramed-
ics to administer a loading-dose infusion without 
the need for infusion pumps (which are complex 
to use) or the counting of drips (an error-prone 
and distracting process), and enabling adminis-
tration of the maintenance dose by emergency 
department nurses immediately after completion 
of the loading dose by having ambulances carry 
study kits containing both field and hospital 
doses. In addition, diligent follow-up of patients 
resulted in a low dropout rate despite the rapidity 
with which patients and their representatives 
needed to make enrollment decisions. These ap-
proaches enabled the FAST-MAG trial to achieve 
several innovative trial-design targets, including 
testing prehospital pharmacologic treatment of 
stroke, enrolling and initiating treatment in a sub-
Table 3. Secondary Efficacy and Safety Outcomes at 3 Months.*
Outcome
Placebo
(N = 843)
Magnesium
(N = 857)
Odds Ratio  
with Magnesium
(95% CI) P Value
Efficacy
Minimal or no disability: modified Rankin 
score of 0 or 1 — no. (%)
311 (36.9) 313 (36.5) 0.98 (0.81–1.20) 0.87
Functional independence: modified Rankin 
score ≤2 — no. (%)
445 (52.8) 449 (52.4) 0.98 (0.81–1.19) 0.87
Neurologic deficit assessed by NIHSS score 
— median (interquartile range)
3 (0–42) 3 (0–19) — 0.28
Global excellent recovery — no. (%)† 0.97 (0.82–1.15) 0.76
Modified Rankin score of 0 or 1 311 (36.9) 313 (36.5) 0.98 (0.81–1.20) 0.87
Barthel Index ≥95 435 (51.6) 427 (49.8) 0.93 (0.77–1.13) 0.47
NIHSS score of 0 or 1 353 (41.9) 349 (40.7) 0.95 (0.79–1.16) 0.66
GOS score of 1 360 (42.7) 365 (42.6) 1.00 (0.82–1.21) 1.00
Global good recovery — no. (%)‡ 1.05 (0.89–1.25) 0.56
Modified Rankin score ≤2 445 (52.8) 449 (52.4) 0.98 (0.81–1.19) 0.88
Barthel Index ≥60 557 (66.1) 593 (69.2) 1.15 (0.94–1.41) 0.18
NIHSS score ≤8 537 (63.7) 569 (66.4) 1.13 (0.92–1.37) 0.26
GOS score of 1 or 2 486 (57.7) 503 (58.7) 1.04 (0.86–1.27) 0.69
Safety
Serious adverse event — no. of patients (%) 422 (50.1) 439 (51.2) 1.05 (0.87–1.27) 0.67
Symptomatic intracranial hemorrhage — 
no. of patients (%)
28 (3.3) 18 (2.1) 0.62 (0.34–1.14) 0.12
Death — no. (%) 131 (15.5) 132 (15.4) 0.99 (0.76–1.29) 0.95
* Values on the Barthel Index range from 0 to 100, with higher values indicating more functional independence. Scores 
on the Glasgow Outcome Scale (GOS) range from 1 to 5, with higher scores indicating worse function. CI denotes  
confidence interval.
† Global excellent recovery was defined by four outcomes (modified Rankin score of 0 or 1, Barthel Index ≥95, NIHSS 
score of 0 or 1, and GOS score of 1, with outcomes analyzed simultaneously with the use of the global test statistic).
‡ Global good recovery was defined by four outcomes (modified Rankin score ≤2, Barthel Index ≥60, NIHSS score ≤8, 
and GOS score of 1 or 2, with outcomes analyzed simultaneously with the use of the global test statistic).
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stantial number of patients in the first 60 minutes 
after stroke onset, and evaluating a neuroprotective 
study agent that was delivered in advance of re-
canalization therapy.
There are several limitations to this study. First, 
the trial was completed over an 8-year period. Al-
though no radical changes in standard therapy 
for acute stroke occurred during this interval, the 
delivery of conventional therapy did evolve over 
that period of time. Second, a small proportion of 
patients were lost to follow-up; nonetheless, re-
tention of patients through the final follow-up 
visit was very high, providing assurance that the 
trial findings are reliable.
Data from the trial on the characteristics of 
patients who were transported to the hospital in 
ambulances within the first 2 hours after stroke 
onset may aid in the design of future trials of 
prehospital treatment of patients with stroke. For 
example, the ratio of patients with hemorrhagic 
stroke to patients with ischemic stroke that would 
be expected in a prehospital trial of hyperacute 
stroke had not been well-delineated previously. 
In the United States, among patients with a focal 
cerebrovascular syndrome (ischemic stroke, tran-
sient ischemic attack, or intracerebral hemor-
rhage but not subarachnoid hemorrhage), 91 to 
94% have cerebral ischemia and 6 to 9% have 
intracerebral hemorrhages.24 However, because 
intracerebral hemorrhages are associated with 
headache and more severe deficits and with a 
younger age than is cerebral ischemia, patients 
with intracerebral hemorrhage are disproportion-
ately represented among patients activating 911 
systems on an early basis. For these reasons, the 
original power calculation projected that the trial 
would enroll double the population-based propor-
tion of patients with intracerebral hemorrhage. 
Actual enrollment showed that the representation 
of patients with intracerebral hemorrhage (24%) 
was triple or quadruple the population-based pro-
portion.
In conclusion, the FAST-MAG trial did not show 
a treatment benefit of magnesium sulfate admin-
istered in the prehospital setting among patients 
in whom hyperacute stroke was suspected. The 
trial did succeed in achieving delivery of the study 
agent to patients with a suspected stroke faster 
than in any previous pivotal trial.
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